Bone Biologics (Bone Biologics) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics COGS-to-Revenue?

Bone Biologics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Bone Biologics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bone Biologics's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Bone Biologics COGS-to-Revenue Historical Data

The historical data trend for Bone Biologics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics COGS-to-Revenue Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Bone Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Bone Biologics COGS-to-Revenue Calculation

Bone Biologics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Bone Biologics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Bone Biologics (NAS:BBLG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bone Biologics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Bone Biologics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bone Biologics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics (Bone Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Executives

Deina H Walsh	officer: Chief Financial Officer	175, MAY STREET, EDISON NJ 08837
Jeff Frelick	officer: Chief Operating Officer	1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd	10 percent owner	4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle	director	481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey	director, 10 percent owner, officer: Chairman of the Board	4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey	director	4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour	10 percent owner	269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc.	director	175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu	director	2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R.	director, officer: CEO and President	106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram	director	12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad	director	132 S. MAPLE DR., BEVERLY HILLS CA 90212